Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule

Inclusion Criteria: * The patient must have given her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 8 weeks of follow-up * The patient is menopausal (amenorrhea) for over 2 years and less than 10 years * The patient has a body mass index \<35 * The patient has sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness. Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant or breastfeeding * The patient is not menopausal (both clinically and biologically) * The patient has a body mass index \> 35 * The patient has a genital prolapse higher than stage 2 with a surgical indication * The patient has stress incontinence with a surgical indication * The patient suffers from vaginismus * Presence of an untreated viral, fungal or bacterial vulvovaginal or urinary infection * Hemorrhagic or neoplastic genital pathologies * Existence of a hormone-dependent tumor, genital bleeding of unknown origin * Current treatments based on antihypertensives, steroid anti-inflammatory drugs, anticoagulants, major antidepressants, aspirin * Known hypersensitivity to hyaluronic acid or mannitol * Known hypersensitivity to Betadine * Known hypersensitivity to Lidocaine * Hypersensitivity to EMLA® * Previous urogynaecological vulvovaginal surgery